The eukaryotic translation initiation factor 2 subunit gamma (EIF2S3) is a critical component of the EIF2 complex, which regulates the initiation phase of protein synthesis. As part of the heterotrimeric EIF2 complex (comprising α, β, and γ subunits), EIF2S3 (the γ-subunit) binds GTP and Met-tRNAi to facilitate ribosome recruitment during translation initiation. This process is tightly regulated, particularly under stress conditions (e.g., nutrient deprivation, viral infection, ER stress), where phosphorylation of the EIF2 α-subunit halts global protein synthesis while allowing selective translation of stress-responsive mRNAs. EIF2S3 antibodies are essential tools for studying these regulatory mechanisms, enabling detection of EIF2S3 expression, localization, and interactions in models of cellular stress, development, and disease. Dysregulation of EIF2 signaling is linked to neurological disorders, cancer, and metabolic syndromes. Notably, EIF2S3 mutations are associated with X-linked intellectual disability and developmental defects, highlighting its role in neurodevelopment. Researchers employ EIF2S3 antibodies in techniques like Western blotting, immunofluorescence, and co-immunoprecipitation to explore its function in translation control, stress responses, and disease pathogenesis. These antibodies also aid in characterizing EIF2 complex assembly and post-translational modifications, providing insights into therapeutic strategies targeting translation machinery.